Publication

Home | Publication

  • De Sarkar N, Patton RD, Doebley A-L, Hanratty B, Kreitzman AJ, Sarthy JF, Ko M, Adil M, Brahma S Meers MP, Janssen DH, Ang LA, Coleman I, Bose A, Dumpit RF, Lucas J, Nunez T, Nguyen HM, McClure HM, Pritchard CC, Schweiuzer MT, Morrissey C, Choudhury AD, Baca SC, Berchuk JE, Freedman ML Ahmed K, Haffner MC, Montgomery RB, Corey E, Henikoff S, Nelson PS, Ha G. Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes. BioRxiV 2022; doi:https://doi.org/10.1101/ 2022.06.21.496879. Under Peer Revision
  • De Sarkar N, Dasgupta S, Chatterjee P, Colman P, Ha G, Ang L, Kholbrenner E, Frank, SB, Nunez T, Saliopante SJ, Corey E, Morrissey C, Van-Allen E, Schweizer M, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS. Genomic attributes of homology directed DNA repair deficiency in metastatic prostate cancer; Journal of Clinical Investigation Insight; JCI Insight 2021,10.1172/jci.insight.152789.
  • Schweizer M, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu E, Konnick E, Nelson P, Pritchard C, Montgomery B. Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples an Metastatic Tissue or Cell-free DNA. Jama Oncology 2021;7(1):107-110.
  • Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. Prostate 2019;79:701-708. landscape and suggests targets for immunotherapy. PLoS One 2017;12:e0183606. *co-first author.
  • Pritchard CC*, Mateo J*, Walsh MF*, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J,nGarraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine 2016;375:443-453.
  • Chattopadhyay E, De Sarkar N, Singh R, Ray A, Roy R, Paul RR, Pal M, Ghose S, Ghosh S, Kabiraj D, Banerjee R, Roy B. Genome-wide mitochondrial DNA sequence variations and lower expression of OXPHOS genes predict mitochondrial dysfunction in oral cancer tissue. Tumour Biol 2016;37:11861-11871.
  • De Sarkar N, Patton RD, Doebley A-L, Hanratty B, Kreitzman AJ, Sarthy JF, Ko M, Adil M, Brahma S, Meers MP, Janssen DH, Ang LA, Coleman I, Bose A, Dumpit RF, Lucas J, Nunez T, Nguyen HM, McClure HM, Pritchard CC, Schweiuzer MT, Morrissey C, Choudhury AD, Baca SC, Berchuk JE, Freedman ML, Ahmed K, Haffner MC, Montgomery RB, Corey E, Henikoff S, Nelson PS, Ha G. Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes. BioRxiV 2022; doi:https://doi.org/10.1101/ 2022.06.21.496879.
  • Coleman IM, De Sarkar N, Morrissey C, Xin L, Roudier MP, Sayar E, Li D, Corey E, Haffner MC, Nelson PS. Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration- Resistant Prostate Cancer, Clin Cancer Res OF1-OF14 doi: https://doi.org/10.1158/ 1078-0432.CCR- 21-4289
  • Doebley AL, Ko M, Liao AH, Cruikshank E, Kikawa C, Santos, Hiatt J, Patton RD, De Sarkar N, Hoge ACH, Chen K, Weber ZT, Adil M, Reichel J, Polak P, Adalsteinsson VA, Nelson PS, Parsons HA, Stover DG, MacPherson D, Ha G. Griffin: Framework for clinical cancer subtyping from nucleosome profiling of cellfree DNA. medRxiv 2021; doi: https://doi.org/10.1101/ 2021.08.31.21262867
  • De Sarkar N, Dasgupta S, Chatterjee P, Colman P, Ha G, Ang L, Kholbrenner E, Frank, SB, Nunez T, Saliopante SJ, Corey E, Morrissey C, Van-Allen E, Schweizer M, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS. Genomic attributes of homology directed DNA repair deficiency in metastatic prostate cancer; Journal of Clinical Investigation Insight; JCI Insight 2021, 10.1172/jci.insight.152789.
  • Sokolova A, Lozano R, Gulati R, Ledet E, De Sarkar N, Higano CS. Nelson P, Olmos D, Schweizer M, Yezefski T, Sartor O, Castro E, Antonarakis E, Cheng H. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations; The Prostate; Reference: The Prostate 2021; 0270-4137.
  • Schweizer M, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu E, Konnick E, Nelson P, Pritchard C, Montgomery B. Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples an Metastatic Tissue or Cell-free DNA. Jama Oncology 2021;7(1):107-110.
  • Baca CS, Takeda DY, Seo J, Hwang J, Ku SY, Arafeh R, Arnoff T , Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei Ca,Cejas P, Lim K, He M, Sheahan A, Nassar A, Berchuck JE, Brown L, Nguyen HM, Coleman IM, Kaipainen A, De Sarkar N, Nelson PS, Morrissey C, Korthauer K, Pomerantz MM, Ellis L, Pasaniuc B, Lawrenson K, Kelly K, Zoubeidi A., Hahn WC, Beltran H, Long HW, Brown M, Corey E, Freedman ML. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nature Communication 2021;12(1):1979.
  • DeLucia D, Cardillo T, Ang A, Labrecque M, Zhang A, Hopkins J, De Sarkar N, Coleman I, da Costa R, Corey R, True L, Haffner M, Schweizer M, Morrissey C, Nelson P, Lee J. Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer. Clinical Cancer Research 202;27:759-767.
  • Saha G, Singh R, Mandal A, Das S, Chattopadhyay E, Panja P, Roy P, De Sarkar N, Gulati S, Ghatak S, Ghosh S, Banerjee S, Roy B, Ghosh B, Chaudhuri D, Arora N, Biswas NK, Sikdar N. A novel hotspot and rare somatic mutation p. A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients. Molecular Medicine 2020;26(1):1-21.
  • Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, Gulati R, Ang L, Chatterjee P, Lucas J, Pritchard C, Risbridger G, Isaacs J, Montgomery B, Morrissey C, Corey E, Nelson PS. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. Cell Report 2020;31:107669.
  • Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL. Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the USA 2019;116:11428-11436.
  • Roy R, Chatterjee A, Das D, Ray A, Singh R, Chattopadhyay E, De Sarkar N, Eccles M, Pal M, Maitra A, Roy B. Genome-wide miRNA methylome analysis in oral cancer: possible biomarkers associated with patient survival. Epigenomics 2019;11(5):473-487.
  • Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. Prostate 2019;79:701-708.
  • Winters BR*, De Sarkar N*, Arora S, Bolouri H, Jana S, Vakar-Lopez F, Cheng HH, Schweizer MT, Yu EY, Grivas P, Lee JK, Kollath L, Holt SK, McFerrin L, Ha G, Nelson PS, Montgomery RB, Wright JL, Lam HM, Hsieh AC. Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. JCI Insight 2019;5(13)e128728. *co-first author.
  • Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, De Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A, Robinson DR, Chinnaiyan AM. Team PSCIPCD. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 2018;173:1770-82.e14.
  • Singh R*, De Sarkar N*, Sarkar S, Roy R, Chattopadhyay E, Ray A, Biswas NK, Maitra A, Roy B. Analysis of the whole transcriptome from gingivo-buccal squamous cell carcinoma reveals deregulated immune landscape and suggests targets for immunotherapy. PLoS One 2017;12:e0183606. *co-first author.
  • Yadav S, De Sarkar N, Kumari N, Krishnani N, Kumar A, Mittal B. Targeted gene sequencing of gall bladder carcinoma identifies high-impact somatic and rare germline mutations. Cancer Genomics- Proteomics 2017;14(6):495-506.
  • Pritchard CC*, Mateo J*, Walsh MF*, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine 2016;375:443-453.
  • Chattopadhyay E, De Sarkar N, Singh R, Ray A, Roy R, Paul RR, Pal M, Ghose S, Ghosh S, Kabiraj D, Banerjee R, Roy B. Genome-wide mitochondrial DNA sequence variations and lower expression of OXPHOS genes predict mitochondrial dysfunction in oral cancer tissue. Tumour Biol 2016;37:11861- 11871.
  • Chattopadhyay E, Singh R, Ray A, Roy R, De Sarkar N, Paul RR, Pal M, Aich R, Roy B. Expression deregulation of mir31 and CXCL12 in two types of oral precancers and cancer: importance in progression of precancer and cancer. Scientific Reports 2016;6:32735.
  • Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, De Sarkar N, Higano C, Yu EY, Coleman R, Schultz N, Fang M, Lange PH, Shendure J, Vessella RL, Nelson PS. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nature Medicine 2016;22:369-378.
  • Roy R, Singh R, Chattopadhyay E, Ray A, De Sarkar N, Aich R, Paul RR, Pal M, Roy B. MicroRNA and target gene expression based clustering of oral cancer, precancer and normal tissues. Gene 2016;593(1):58-63.
  • Datta S, Ray A, Singh R, Mondal P, Basu A, De Sarkar N, Majumder M, Maiti G, Baral A, Jha GN, Mukherjee I, Panda C, Chowdhury S, Ghosh S, Roychowdhury S, Roy B. Sequence and expression variations in 23 genes involved in mitochondrial and non-mitochondrial apoptotic pathways and risk of oral leukoplakia and cancer. Mitochondrion 2015;25:28-33.
  • De Sarkar N, Roy R, Mitra JK, Ghose S, Chakraborty A, Paul RR, Mukhopadhyay I, Roy B. A quest for miRNA biomarker: a track back approach from gingivo buccal cancer to two different types of precancers. PLoS One 2014;9: e104839.
  • Roy R, De Sarkar N, Ghose S, Paul RR, Pal M, Bhattacharya C, Roy Chowdhury SK, Ghosh S, Roy B. Genetic variations at microRNA and processing genes and risk of oral cancer. Tumor Biology 2014;35(4):3409-3414.
  • Roy R, De Sarkar N, Ghose S, Paul RR, Ray A, Mukhopadhyay I, Roy B. Association between risk of oral precancer and genetic variations in microRNA and related processing genes. Journal of Biomedical Sciences 2014;21(1):48.
  • Bhattacharya S, De Sarkar N, Banerjee P, Banerjee S, Mukherjee S, Chattopadhyay D, Mukhopadhyay A. Effects of arsenic toxicity on germination, seedling growth and peroxidase activity in Cicer arietinum. Int. J. Agric. Food Sci 2012;2:131-137.
  • De Sarkar N*, Majumder M*, Roy B. Differential haplotype amplification leads to misgenotyping of heterozygote as homozygote when using single nucleotide mismatch primer. Electrophoresis 2012;33:3564-3573. *co-first author.
  • De Sarkar N, Patton RD*, Doebley AL, Hanratty B, Kreitzman AJ, Sarthy JF, Ko M, Adil M, Brahma S, Meers MP, Janssens DH, Ang LA, Coleman I, Bose A, Dumpit RF, Lucas JM, Nunez TA, Nguyen HM, McClure HM, Pritchard CC, Schweizer MT, Morrissey C, Choudhury AD, Baca SC, Berchuck JE, Freedman ML, Ahmad K, Haffner MC, Montgomery B, Corey E, Henikoff S, Nelson PS, Ha G. Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes. Under revision, Cancer Discovery: CD-22-0692. *co-first author.
  • Doebley AL, Ko M, Liao AH, Cruikshank E, Kikawa C, Santos, Hiatt J, Patton RD, De Sarkar N, Hoge ACH, Chen K, Weber ZT, Adil M, Reichel J, Polak P, Adalsteinsson VA, Nelson PS, Parsons HA, Stover DG, MacPherson D, Ha G. Griffin: Framework for clinical cancer subtyping from nucleosome profiling of cellfree DNA. Nature communications. Accepted.

Design & Developed By Diligent ITech Private Limited